Table 1.
Overview of the antibodies and compounds specifying clone, dose, depletion check and days of dosing in relation to sensitization on day −5 and challenge on day 0
| Antibody/compound | Clone | Dose/mouse | Days of dosing | Depletion check |
|---|---|---|---|---|
| Rat anti-mouse CD25 mAb | PC.61·5 | 200 μg | Days −16 and −13 | Days −12 and −5 |
| Rat anti-mouse CD4 mAb + rat anti-mouse CD8 mAb | CD4: GK1·5 | 1 mg | Group 1: days −6 and 3 | Day 4 |
| CD8: 53·6.72 | ||||
| Group 2: day 2 | ||||
| Rat anti-mouse TNF-α mAb | XT3·11 | 500 μg | Days −6, −3, 1, 2, 5 and 8 | |
| Rat anti-mouse IL-10R mAb | 1B1·3A | 250 μg | Days −6, −3, 1, 2, 5 and 8 | |
| Rat IgG1 | HRPN | 500 μg | Days −6, −3, 1, 2, 5 and 8 | |
| CTLA-4-Ig | n.a. | 500 μg | Days −6, −3, 1, 2, 5 and 8 | |
| Recombinant human Fc-G1 | Human Fc-G1 | 500 μg | Days −6, −3, 1, 2, 5, and 8 |
mAb = monoclonal antibody; TNF = tumour necrosis factor; IL = interleukin; Ig = immunoglobulin; CTLA-4 = cytotoxic T lymphocyte antigen-4; n.a. = not applicable.